Understanding how CAR-T cell therapy works is key to making informed decisions about treatment. This category breaks down the science and technology behind CAR-T in a clear, patient-friendly way—covering how T cells are collected, engineered, and reinfused to fight cancer and other diseases. Learn about the latest advancements in CAR design, safety enhancements, gene-editing techniques, and how China’s leading researchers are making CAR-T therapy more effective and widely accessible. Whether you’re newly diagnosed or exploring treatment options, this section helps demystify the technology behind one of the most innovative therapies in modern medicine.
CAR-T cell therapy has revolutionized the treatment of several blood cancers, including leukemia, lymphoma, and multiple myeloma. Researchers are also developing innovative CAR-T therapies for solid tumors such as gastric, liver, lung, and pancreatic cancers. Learn which cancers may benefit from this breakthrough immunotherapy.
CAR-T therapy combined with stem cell transplantation is emerging as a powerful strategy for high-risk blood cancer patients. Dr. Kai Hu explains how bridging and consolidation approaches improve remission depth, safety, and long-term survival.
CAR-T therapy is moving beyond cancer, showing promise against infections, fibrosis, aging, and even Alzheimer’s disease—signaling a new era of cellular immunotherapy.
In vivo CAR-T therapy is an emerging treatment that “trains” your immune cells to fight cancer directly inside your body—without weeks of lab work. This promising approach could make powerful cancer care faster, easier, and available to more patients worldwide.
By September, 2024, Six CAR T-cell therapies have been approved in China, they are Yescarta, Carteyva, Fucaso, CNCT19, Zevor-cel and Carvykti.
A Phase I trial led by Stanford investigators has shown that CD22-targeted CAR-T therapy achieved an overall response rate of 68% and complete remission in 53% of patients with R/R large B-cell lymphoma relapsing after CAR19. Published in The Lancet, the study highlights CD22 as a promising new target offering hope for patients with few treatment options.
CAR T-cell therapy has demonstrated significant promise in treating hematologic malignancies, with several CAR T-cell therapies already approved for the treatment of blood cancers. Additionally, numerous clinical trials are currently
In CAR T-cell therapy, CD19, CD20, CD22, CD7, BCMA are commly used tumor markers in the treatment of blood cancers.
Tumor markers are crucial in CAR T-cell therapy for identifying specific cancer cell antigens to target, personalizing treatment, monitoring effectiveness, and assessing disease progression.
Tumor markers are crucial in cancer treatment as they help diagnose, monitor disease progression, evaluate treatment response, and guide therapeutic decisions.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.